BOSTON AND GENEVA, SWITZERLAND, Sept. 20, 2022 (GLOBE NEWSWIRE) – SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company in the healthcare, will host its first In-Personally Invested Day today at the PUBLIC Hotel in New York City. The event will begin at 1:30 PM EST and is expected to conclude at approximately 5:30 PM EST.
- Troy Cox, Chairman of the Board
- Dr. Georgie Camplung, CEO and Co-Founder
- Ken Friedman, Chief Revenue Officer
- Peter Casasanto, CEO of Biopharmaceuticals
- Dr. Philip Mineo, Medical Director
- Abhi Verma, Head of Technology
- Dr. Zhenyu Xu, Chief Scientific Officer
- Ross Moken, Chief Financial Officer
Today’s Investor Day will provide an opportunity for investors to learn from the company’s executive team about the key tradeoffs and strategies that will help drive SOPHiA Genetics’ long-term growth.
Due to limited capacity, prior registration is required to attend in person. For more information, interested parties can contact Investor Relations at [email protected]
In addition, the event will be broadcast live, and all interested parties will be invited to access the webcast from the investor relations section of the company’s website.
About Sophia Genetics
SOPHiA GENETICS (Nasdaq: SOPH) is a software company dedicated to establishing the practice of data-driven medicine as the standard for life sciences care and research. He is the creator of the SOPHiA DDM™ platform, a cloud-native platform capable of analyzing data and generating insights from complex multimedia datasets and various diagnostic methods. The SOPHiA DDM™ platform and related solutions, products and services are currently used by an extensive network of hospitals, laboratories and biopharmaceutical organizations globally. For more information, visit SOPHiAGENETICS.COM, or connect on Twitter, LinkedIn, Facebook and Instagram. Where others see the data, we see the answers
SOPHiA GENETICS products are for research use only and are not for use in diagnostic procedures, unless otherwise stated. The information in this press release relates to products that may or may not be available in different countries and, if applicable, may or may not have received market approval or authorization by a government regulatory body for different indications for use. Please contact [email protected] for appropriate product information for your country of residence.
Forward-looking statements of SOPHIA GENETICS:
This press release contains statements that constitute forward-looking statements. All statements other than statements of historical facts contained in this press release, including statements regarding future results of operations, financial position, business strategy, products and technology, as well as management’s plans and objectives for future operations, are forward-looking statements. Forward-looking statements are based on the beliefs and assumptions of our management and on information currently available to our management. These statements are subject to risks and uncertainties, and actual results may differ materially from those expressed or implied in the forward-looking statements due to various factors, including those described in our filings with the US Securities and Exchange Commission. No guarantees can be given that such results in the future will be achieved. These forward-looking statements contained in this press release speak only as of the date of this release. We expressly disclaim any obligation or undertaking to update these forward-looking statements contained in this press release to reflect any change in our expectations or any change in events, circumstances or conditions on which such statements are based, unless required by applicable law. No representations or warranties are made (express or implied) about the accuracy of any such forward-looking statements.
Head of Investor Relations
Senior Director of Media and Communications